Science Explorer Back to mapMap
Discussion
Institution · Kindai University

Most cited papers from Kindai University

Kindai University

What are the most cited papers from Kindai University?

The most cited paper from Kindai University is "Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma" (Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al., 2009), with 8,331 citations. Next come "Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma" (7,547) and "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial" (7,405).

Showing 50 of 60 papers. Every paper with more than 964 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony S.K. Mok, Yi-Long Lung Cancer Wu, Sumitra Thongprasert et al. · New England Journal of Medicine Open access 19 Aug 2009 8,331
2 Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn et al. · New England Journal of Medicine Open access 13 May 2020 7,547
3 Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet Open access Aug 2010 7,405
4 Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Masatoshi Kudo et al. · The Lancet Open access Mar 2018 5,578
5 Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry et al. · The Lancet Open access 20 Apr 2017 4,384
6 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Tetsuya Mitsudomi et al. · The Lancet Oncology 19 Dec 2009 4,130
7 Chemokines Albert Zlotnik, Osamu Yoshie · Immunity Open access Feb 2000 3,882
8 Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Jordi Bruix et al. · The Lancet Open access 5 Dec 2016 3,732
9 Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer Alice Tsang Shaw et al. · New England Journal of Medicine Open access Jun 2013 3,429
10 First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer Benjamin J. Solomon, Tony S.K. Mok, Dong‐Wan Kim et al. · New England Journal of Medicine Open access 3 Dec 2014 3,251
11 Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors 2 Jan 2021 2,743
12 Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle et al. · The Lancet Oncology Open access 10 Sep 2020 2,600
13 Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew Xiuxuan Zhu et al. · The Lancet Oncology 3 Jun 2018 2,555
14 Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Open access 12 Oct 2017 2,317
15 Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update Masao Omata et al. · Hepatology International Open access 15 Jun 2017 2,208
16 International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study Franck Pagès et al. · The Lancet May 2018 2,133
17 JENDL-4.0: A New Library for Nuclear Science and Engineering Keiichi SHIBATA, Osamu Iwamoto, Tsuneo NAKAGAWA et al. · Journal of Nuclear Science and Technology 2011 2,086
18 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi et al. · New England Journal of Medicine Open access 11 Dec 2019 2,026
19 Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine Open access 21 Aug 2013 1,936
20 The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) Satoshi Umemura et al. · Hypertension Research Open access 2 Aug 2019 1,903
21 Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Brian I. Rini et al. · The Lancet 4 Nov 2011 1,861
22 Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial Richard S. Finn et al. · Journal of Clinical Oncology 2 Dec 2019 1,842
23 Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda et al. · Journal of Hepatology Open access 11 Dec 2021 1,749
24 Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial Hisashi Saji, Morihito Okada, Masahiro Tsuboi et al. · The Lancet Apr 2022 1,739
25 High performance plasma amyloid-β biomarkers for Alzheimer’s disease Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne et al. · Nature 31 Jan 2018 1,737
26 Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial Andrew Xiuxuan Zhu et al. · The Lancet Oncology 18 Jan 2019 1,680
27 Mordred: a molecular descriptor calculator Hirotomo Moriwaki, Yu‐Shi Tian, Norihito Kawashita et al. · Journal of Cheminformatics Open access 6 Feb 2018 1,634
28 Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer Kim N. Chi, Neeraj Agarwal, Anders S Bjartell et al. · New England Journal of Medicine Open access 31 May 2019 1,573
29 Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Ghassan K. Abou‐Alfa et al. · NEJM Evidence Open access 6 Jun 2022 1,534
30 All-solid-state Z-scheme in CdS–Au–TiO2 three-component nanojunction system Hiroaki Tada, Tomohiro Mitsui, Tomokazu Kiyonaga et al. · Nature Materials 9 Sep 2006 1,487
31 Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Yuri E. Nikiforov et al. · JAMA Oncology Open access 14 Apr 2016 1,404
32 Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara et al. · New England Journal of Medicine Open access 10 Jan 2002 1,376
33 Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours Jérôme Galon et al. · The Journal of Pathology Open access 11 Oct 2013 1,370
34 Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine Open access 29 May 2020 1,352
35 High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast Material Tomonori Kanda, Kazunari Ishii, Hiroki Kawaguchi et al. · Radiology 17 Dec 2013 1,350
36 Insights into Land Plant Evolution Garnered from the Marchantia polymorpha Genome John L. Bowman et al. · Cell Open access113 authors Oct 2017 1,314
37 NASH limits anti-tumour surveillance in immunotherapy-treated HCC Dominik Reinhard Pfister et al. · Nature Open access110 authors 24 Mar 2021 1,304
38 Regulation and function of ascorbate peroxidase isoenzymes Shigeru Shigeoka · Journal of Experimental Botany Open access 15 May 2002 1,296
39 Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study Joong‐Won Park, Minshan Chen, M. Colombo et al. · Liver International Open access 5 Mar 2015 1,288
40 Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma Yuichiro Doki et al. · New England Journal of Medicine Open access 2 Feb 2022 1,275
41 The Chemokine Superfamily Revisited Albert Zlotnik, Osamu Yoshie · Immunity Open access May 2012 1,266
42 Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Thomas C. C. Yau et al. · JAMA Oncology Open access Oct 2020 1,243
43 Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial Yi-Long Lung Cancer Wu, Ying Cheng, Xiangdong Zhou et al. · The Lancet Oncology 25 Sep 2017 1,232
44 Role of oxygen vacancy in the plasma-treated TiO2 photocatalyst with visible light activity for NO removal Isao Nakamura, Nobuaki Negishi, Shuzo Kutsuna et al. · Journal of Molecular Catalysis A Chemical Nov 2000 1,230
45 Understanding Oxidative Stress and Antioxidant Functions to Enhance Photosynthesis Christine Helen Foyer, Shigeru Shigeoka · PLANT PHYSIOLOGY Open access 2 Nov 2010 1,229
46 CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth Takatsugu Ishimoto et al. · Cancer Cell Open access Mar 2011 1,206
47 Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma Richard S. Finn, Masafumi Ikeda, Andrew Xiuxuan Zhu et al. · Journal of Clinical Oncology Open access 27 Jul 2020 1,188
48 Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia Han‐Xiang Deng et al. · Nature Open access 19 Aug 2011 1,188
49 Galactinol and Raffinose Constitute a Novel Function to Protect Plants from Oxidative Damage Ayako Nishizawa‐Yokoi, Yukinori Yabuta, Shigeru Shigeoka · PLANT PHYSIOLOGY Open access 23 May 2008 1,145
50 Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial Jordi Bruix, Tadatoshi Takayama, Vincenzo Mazzaferro et al. · The Lancet Oncology 8 Sep 2015 1,128

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.